<DOC>
	<DOCNO>NCT01648257</DOCNO>
	<brief_summary>This single-center , randomize , open-label , balance , 3 way crossover study ( 3 period ) healthy adult subject . During period , subject receive single dose GSK1265744 oral formulation fast state serial PK sample 168 hour ( 8 day ) safety assessment perform . Each period separate washout period least 14 day follow-up visit occur 10 14 day last dose study drug .</brief_summary>
	<brief_title>Relative Bioavailability Study GSK1265744 Formulations</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin = &lt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinically significant abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 64 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation , bilateral salpingooophorectomy hysterectomy ; postmenopausal define protocol ; childbearing potential agrees use one contraception method list protocol . Male subject female partner childbearing potential must agree use one contraception method . This criterion must follow time first dose study medication 14 day last dose study medication . Body weight &gt; = 50 kilogram ( kg ) men &gt; = 45 kg woman body mass index ( BMI ) within range 18.5 31.0 kg/ ( meter square ) m^2 ( inclusive ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody . History regular alcohol consumption within 6 month study . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new investigational chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive urine human chorionic gonadotropin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . The subject 's systolic blood pressure outside range 90140 millimeter mercury ( mmHg ) , diastolic blood pressure outside range 45 90 mmHg . History clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>healthy subject</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>HIV</keyword>
	<keyword>GSK1265744</keyword>
</DOC>